Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Gilteritinib (ASP2215) 是一种 FLT3 抑制剂 (IC50:0.29 nM),也是一种 AXL 抑制剂 (IC50:0.73 nM),具有 ATP 竞争性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 358 | 现货 | ||
2 mg | ¥ 519 | 现货 | ||
5 mg | ¥ 828 | 现货 | ||
10 mg | ¥ 1,230 | 现货 | ||
25 mg | ¥ 1,970 | 现货 | ||
50 mg | ¥ 2,890 | 现货 | ||
100 mg | ¥ 4,280 | 现货 | ||
500 mg | ¥ 7,890 | 现货 | ||
1 g | ¥ 10,600 | 现货 |
产品描述 | Gilteritinib (ASP2215) is a potent inhibitor at the FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preClinicalal studies, gilteritinib showed strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 Clinicalal trials for acute myeloid leukemia. |
靶点活性 | FLT3:0.29 nM, c-Kit:230 nM, TYK1/LTK:0.35 nM, EML4-ALK:1.2 nM, Axl:0.73 nM |
体外活性 | 在测试的78种酪氨酸激酶中,Gilteritinib (ASP2215) 在1 nM浓度下对FLT3、白细胞酪氨酸激酶 (LTK)、间变性淋巴瘤激酶 (ALK) 和AXL激酶的抑制率超过50%,其中对FLT3的IC50值为0.29 nM,大约是对c-KIT的800倍。Gilteritinib在1 nM (包括FLT3、LTK、ALK和AXL) 或5 nM (包括TRKA、ROS、RET和MER) 的浓度下,对测试的78种激酶中的8种的活性抑制率超过50%。其对FLT3和AXL的IC50分别为0.29 nM和0.73 nM。Gilteritinib抑制FLT3的能力约为其抑制c-KIT所需浓度的800倍(230 nM)。Gilteritinib对内源性表达FLT3-ITD的MV4-11和MOLM-13细胞的抗增殖活性经5天处理后进行了评估,其对MV4-11和MOLM-13细胞生长的抑制的平均IC50值分别为0.92 nM (95% CI: 0.23-3.6 nM) 和2.9 nM (95% CI: 1.4-5.8 nM)。MV4-11细胞生长的抑制伴随着FLT3磷酸化的抑制。与载体控制细胞相比,经过0.1 nM、1 nM和10 nM Gilteritinib处理2小时后,磷酸化FLT3水平分别为57%、8%和1%。此外,低至0.1 nM或1 nM的剂量就可抑制磷酸化的ERK、STAT5和AKT的水平,这些都是FLT3激活的下游靶标。为研究Gilteritinib对AXL抑制的效果,对表达外源性AXL的MV4-11细胞进行了Gilteritinib处理,在1 nM、10 nM和100 nM的浓度下4小时处理后,磷酸化AXL水平分别下降了38%、29%和22%。 |
体内活性 | In MV4-11 xenografted-mice, the concentration of Gilteritinib (ASP2215) in tumors is more than 20-fold higher than that in plasma with oral administration of Gilteritinib at 10 mg/kg for 4 days. Treatment of Gilteritinib for 28 days results in dose-dependent inhibition of MV4-11 tumor growth and induces complete tumor regression at more than 6 mg/kg. Besides, Gilteritinib decreases tumor burden in bone marrow and prolonged the survival of mice intravenously transplanted with MV4-11 cells. |
激酶实验 | The kinase inhibitory activity of Gilteritinib is tested against a panel of 78 tested kinases using ATP concentrations that are approximately equal to the Km value for each kinase in a TK-ELISA or off-chip mobility shift assay. Initially, two concentrations of Gilteritinib (1 nM and 5 nM) are tested to assess each compound's inhibitory effect on TK activity. Further studies are then conducted using a dose range of Gilteritinib to determine IC50 values for kinases in which activity is inhibited by >50% with 1 nM Gilteritinib as well as for c-KIT. TK-ELISA and MSA assays are used to conduct IC50 studies for FLT3, LTK, AXL, and c-KIT; the HTRF KinEASE-TK assay is performed to assess the IC50 value of echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) |
细胞实验 | Gilteritinib is dissolved in DMSO and stored, and then diluted with appropriate media before use.The effect of Gilteritinib on MV4-11 and MOLM-13 cells is assessed using the CellTiter-Glo Luminescent Cell Viability Assay. Subsequent studies are conducted to examine the effect of Gilteritinib and Quizartinib on Ba/F3 cells expressing either FLT3-ITD, FLT3-D835Y, FLT3-ITD-D835Y, FLT3-ITD-F691 L, or FLT3-ITD-F691I. MV4-11 and MOLM-13 cells are treated with DMSO or increasing concentrations of Gilteritinib (0.01, 0.1, 1, 10, and 100 nM) for 5 days, and cell viability is measured using CellTiter-Glo |
动物实验 | MiceAntitumor activity is evaluated in nude mice transplanted with MV4-11 AML cells. The pharmacokinetics in xenografted mice is also investigated. MV4-11 xenografted-mice are treated with oral administration of Gilteritinib at 10 mg/kg for 4 days. Treatment of Gilteritinib for 28 days results in dose-dependent inhibition of MV4-11 tumor growth and induces complete tumor regression at more than 6 mg/kg |
别名 | 吉列替尼, ASP2215 |
化合物与蛋白结合的复合物 |
Crystal structure of FLT3 in complex with gilteritinib |
分子量 | 552.71 |
分子式 | C29H44N8O3 |
CAS No. | 1254053-43-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 1mg/ml
Ethanol: 4 mg/mL(7.2 mM)
H2O: Insoluble
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol | 1 mM | 1.8093 mL | 9.0463 mL | 18.0927 mL | 45.2317 mL |
5 mM | 0.3619 mL | 1.8093 mL | 3.6185 mL | 9.0463 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Gilteritinib 1254053-43-4 Angiogenesis Tyrosine Kinase/Adaptors FLT TAM Receptor c-Kit FLT3 CD135 Axl inhibit Mer ASP-2215 Tyro3 吉列替尼 Fms like tyrosine kinase 3 Cluster of differentiation antigen 135 ASP 2215 ASP2215 Inhibitor inhibitor